To determine whether C-604 inhibited GWL in human cells, we measured phosphorylation levels of canonical GWL substrates ENSA(S67) and ARPP19(S62) in prometaphase-arrested HCC1395 (breast cancer), U2OS (osteosarcoma), RPE-1 (non-transformed) and HeLa (cervical cancer) cells treated with C-604. This evidence concerns the gene ARPP19 and breast carcinoma.